Financial Performance - The company's operating revenue for 2021 was ¥614,683,452.35, representing a 17.28% increase compared to ¥524,123,427.37 in 2020[20]. - The net profit attributable to shareholders in 2021 was ¥27,654,228.04, a significant turnaround from a loss of ¥25,025,702.16 in 2020, marking a 210.50% increase[20]. - The net profit after deducting non-recurring gains and losses was ¥5,591,250.83 in 2021, compared to a loss of ¥42,196,910.19 in 2020, reflecting a 113.25% improvement[20]. - The company's total assets increased by 23.37% to ¥2,697,511,886.43 at the end of 2021, up from ¥2,186,566,003.25 at the end of 2020[20]. - The net assets attributable to shareholders rose by 36.04% to ¥2,324,400,644.26 at the end of 2021, compared to ¥1,708,652,006.75 at the end of 2020[20]. - The company reported a basic earnings per share of ¥0.260 in 2021, a significant increase from a loss of ¥0.240 per share in 2020, representing a 208.33% improvement[20]. - The weighted average return on equity was 1.52% in 2021, recovering from -1.44% in 2020[20]. - The company generated a net cash flow from operating activities of ¥12,088,247.37 in 2021, a 161.35% increase from a negative cash flow of ¥19,703,010.29 in 2020[20]. - Total revenue for 2021 reached ¥614,683,452.35, representing a year-on-year increase of 17.28% compared to ¥524,123,427.37 in 2020[63]. - Revenue from pharmaceutical technology services was ¥281,289,134.51, accounting for 45.76% of total revenue, with a year-on-year growth of 24.91%[63]. - The revenue from raw materials and intermediates surged by 3,174.77% to ¥102,258,145.15, significantly increasing its contribution to total revenue[63]. - Domestic sales accounted for 98.54% of total revenue at ¥605,726,002.55, with a year-on-year increase of 15.58%[63]. - Direct sales contributed ¥435,423,553.92, representing 70.84% of total revenue, with a growth of 23.72% compared to the previous year[63]. Market and Industry Outlook - The biopharmaceutical industry is projected to grow significantly, with the global market expected to reach $456.7 billion by 2024, reflecting a compound annual growth rate (CAGR) of approximately 9.8% from 2019[31]. - China's biopharmaceutical market is anticipated to grow to ¥712.5 billion by 2024, with a CAGR of about 18.0% from 2019[32]. - The global CRO market size increased from 44.3 billion USD in 2015 to 62.6 billion USD in 2019, and is expected to reach 96 billion USD by 2024, with a CAGR of approximately 8.9% from 2019 to 2024[35]. - The overall CRO industry in China is characterized by a fragmented market with low concentration, presenting significant growth opportunities due to increasing pharmaceutical R&D investments[36]. - The pharmaceutical market in China is projected to grow from RMB 1,633 billion in 2019 to RMB 2,228 billion by 2024, with a compound annual growth rate (CAGR) of approximately 6.42%[107]. Research and Development - The company has established six high-end formulation R&D platforms, significantly improving the success rate of drug project development[37]. - The company is actively developing multiple small molecule generic drugs and APIs, with ongoing projects progressing smoothly[51]. - The company has submitted a new drug application for the recombinant tumor necrosis factor project, awaiting approval from the National Medical Products Administration (NMPA)[51]. - The company has completed process validation for the recombinant human nerve growth factor eye drops project, transitioning from a lyophilized powder injection to an eye drop formulation[51]. - The company has submitted a generic drug application for parecoxib sodium injection, which is intended for short-term treatment of postoperative pain[51]. - The company has established a database of pharmaceutical experts to support its research and development efforts and ensure compliance with regulatory requirements[46]. - The company is focused on optimizing its talent structure and building research platforms to strengthen its independent R&D capabilities[51]. - The company has a strong talent pool with over 60% of its R&D team holding master's or doctoral degrees, and 90% of the core team members have extensive experience in project development[56]. - The company has invested 200 million RMB in new technology for drug development, aiming to improve production efficiency by 30%[145]. - The company plans to increase its R&D budget by 40% in 2022, focusing on innovative therapies[145]. Governance and Compliance - The company emphasizes the importance of accurate financial reporting and has declared the financial report to be true, accurate, and complete[4]. - The company has established a comprehensive governance structure to ensure compliance with relevant laws and regulations[124]. - The company has established a profit distribution policy, stating that cash dividends should not be less than 20% of the distributable profits for the year[125]. - The board of directors consists of 9 members, including 3 independent directors, in compliance with relevant regulations[126]. - The company has a complete and independent governance structure, ensuring independence in assets, personnel, finance, and operations from the controlling shareholder[129]. - The company has established a strict external guarantee system, with no guarantees provided for the controlling shareholder or its controlled enterprises[135]. - The company held three temporary shareholder meetings in 2021, with investor participation rates of 57.15%, 58.14%, and 50.42% respectively[136]. - The company has emphasized the importance of independent oversight in its governance practices, as evidenced by the appointment of new independent directors[140]. - The internal control self-assessment report indicates that there were no significant defects in internal controls during the reporting period[167]. - The internal control audit report confirmed that the company maintained effective internal controls related to financial reporting as of December 31, 2021[171]. Environmental Responsibility - HaiTe Biopharma reported a total chemical oxygen demand (COD) discharge of 0.713 tons per year, which is below the approved limit of 2.4 tons per year[174]. - The company has a wastewater treatment capacity of 500 tons per day, ensuring that all wastewater is treated to meet discharge standards[175]. - HaiTe Biopharma's ammonia nitrogen discharge is 0.039 tons per year, significantly lower than the approved limit of 0.45 tons per year[174]. - The company has established a comprehensive environmental management system and has a dedicated team for environmental protection[175]. - HaiTe Biopharma has implemented an emergency response plan for environmental incidents, which has been filed with the environmental protection department[177]. - The company has conducted regular drills to ensure effective response to potential environmental emergencies[177]. - HaiTe Biopharma has reported no administrative penalties related to environmental issues during the reporting period[179]. Strategic Initiatives - The company is focused on expanding its product pipeline in the fields of neurology and oncology, enhancing its market position[59]. - The company is constructing a new antiviral production facility, with the 103 antiviral workshop expected to be delivered within the year[115]. - The company is actively monitoring national pharmaceutical policies to mitigate risks associated with drug registration and market competition[116]. - The company aims to reduce reliance on single products through the acquisition of Hankan Pharmaceutical, enhancing its research and development capabilities[100]. - The company is in the process of acquiring a 6.9416% stake in Beijing Shadong Biological Technology Co., Ltd., indicating strategic expansion efforts[158]. - The company is also seeking to apply for a comprehensive credit facility from banks, which may enhance its financial flexibility[158]. Employee Engagement and Development - The total number of employees at the end of the reporting period was 1,143, with 268 in the parent company and 875 in major subsidiaries[160]. - The company employed 592 technical personnel, 336 production personnel, and 86 sales personnel, reflecting a strong focus on technical expertise[160]. - The educational background of employees included 11 with doctoral degrees, 186 with master's degrees, and 484 with bachelor's degrees, indicating a highly educated workforce[160]. - The company maintained a comprehensive salary system, ensuring timely payment of salaries, holiday bonuses, performance bonuses, and year-end bonuses despite the ongoing pandemic[161]. - In 2021, the company organized three training sessions focusing on various aspects of the pharmaceutical industry, enhancing employee knowledge and skills[162]. - The company conducted 8 Hiteck talk events to foster a culture of learning and sharing among employees, promoting engagement and collaboration[162]. Risks and Challenges - The company faces various risks including industry policy risks, new drug registration and market risks, and new drug development risks, which are detailed in the management discussion and analysis section[5]. - The report does not provide specific user data or performance guidance for the upcoming periods[5]. - There is no indication of market expansion or mergers and acquisitions in the current report[5]. - The CPT project is undergoing a Phase III clinical trial and is awaiting approval, with potential market risks if not included in the medical insurance directory[117]. - The high-end API production base project is significant, with potential risks related to market demand and policy changes affecting project viability[119].

武汉海特生物制药股份有限公司 2022 年第一季度报告全文 证券代码：300683 证券简称：海特生物 公告编号：2022-020 武汉海特生物制药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 166,204,766.30 | 157,828,324.48 | 5.31% | | 归属于上市公司股东的净利润（元） | 7,690,523 ...

证券代码：300683 证券简称：海特生物 公告编号：2021-062 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 武汉海特生物制药股份有限公司 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 2021 年第三季度报告 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末比上年 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 减 | 同期增减 | | | 营业收入（元） | 166,826,194.88 | 6.77% | 392,370,845.33 | 12.56% | | 归属于上市公司股东的 净利润（元） | ...

武汉海特生物制药股份有限公司 2021 年半年度报告全文 武汉海特生物制药股份有限公司 2021 年半年度报告 2021-052 2021 年 08 月 1 武汉海特生物制药股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人陈亚、主管会计工作负责人夏汉珍及会计机构负责人(会计主管 人员)羡雯声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司在生产经营中可能存在产业政策风险 、CPT 的研发、新药注册与市场 风险、高端原料药生产基地 I 期项目的实施风险 、新药研发、募投项目实施风 险等风险，有关风险因素具体内容在本报告第三节"管理层讨论与分析"之"十、 公司面临的风险和应对措施"章节中予以描述，敬请投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第 ...

证券代码：300683 证券简称：海特生物 公告编号：2021-036 武汉海特生物制药股份有限公司 关于参加湖北上市公司2021年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 召开时间：2021年6月24日（星期四）15:30-17:00 召开方式：网络在线交流方式。 一、说明会情况 为便于广大投资者更深入全面地了解公司情况，公司决定以网络在线交流方 式参加湖北证监局、湖北省上市公司协会、深圳市全景网络有限公司联合举办的 "湖北辖区上市公司2021年度投资者网上集体接待日活动"。公司将积极参与活 动并围绕2020年度业绩、公司治理、经营状况、可持续发展情况等投资者所关心 的问题，通过互动平台与投资者进行沟通交流。 二、说明会召开时间 本次说明会召开时间为 2021 年 6 月 24 日（星期四）15:30-17:00。 三、参加人员 公司出席本次年度网上说明会的人员有公司副总经理、董事会秘书陈煌先 生，财务总监夏汉珍女士。 四、投资者参加方式 本次说明会将通过网上平台采取网络远程的方式举行，投资者可通过互 ...

Financial Performance - The company reported a significant loss due to the removal of its main product, Nerve Growth Factor injection, from the national medical insurance catalog, leading to a decline in sales[5]. - The company's operating revenue for 2020 was ¥524,123,427.37, a decrease of 15.49% compared to ¥620,163,188.70 in 2019[25]. - The net profit attributable to shareholders in 2020 was -¥25,025,702.16, representing a decline of 139.70% from ¥63,035,065.41 in 2019[25]. - The net cash flow from operating activities was -¥19,703,010.29 in 2020, down 131.26% from ¥63,027,543.20 in 2019[25]. - The total income of 17,171,208.03 in the current period, a decrease from 27,950,105.56 in the previous year, representing a decline of approximately 38.5%[32]. - The company reported a quarterly operating revenue of ¥175,529,048.11 in Q4 2020, showing a sequential increase from previous quarters[28]. - The company incurred a net loss of -¥14,499,253.88 in Q4 2020, following losses in the previous quarters[28]. - The company has indicated uncertainty regarding its ability to continue as a going concern, as reflected in its financial performance[25]. Research and Development - R&D expenses increased by CNY 23.47 million compared to 2019, with R&D costs accounting for 16.43% of revenue, up from 10.10% in 2019[5]. - The company is developing a new drug, CPT, which has completed data lock and unblinding for its Phase III clinical trial, with results meeting expectations[9]. - The company plans to submit a New Drug Application (NDA) for CPT, pending regulatory review and approval processes[10]. - The company has a strong focus on R&D, with its main product "Jinlujie" being the world's first commercialized nerve growth factor new drug, launched in 2003[40]. - The company is advancing multiple projects, including the CPT project, which has completed Phase III clinical trials and is preparing for NDA submission[73]. - The CPT project has received significant funding and has multiple invention patents granted in 17 countries and regions[73]. - The company’s R&D services cover various therapeutic areas, including cardiovascular, respiratory, digestive, and endocrine systems[36]. - The company has established a comprehensive drug development service from R&D to clinical and production stages, enhancing its service offerings[36]. Market and Product Development - The company is focused on expanding its market presence with new products, particularly CPT, which could enhance its competitiveness if included in the medical insurance catalog[8]. - The company aims to increase the proportion of self-developed products through independent research and development of small molecule chemical drugs with good market prospects[58]. - The company is focusing on expanding its product offerings in the neurology and oncology fields, with a focus on innovative drug development[67]. - The company has established a comprehensive sales service network, collaborating with major distributors like Sinopharm and China Resources[67]. - The company has launched online promotional activities for its NGF product and conducted charitable drug donation campaigns to support patients during the pandemic[76]. Assets and Investments - The total assets at the end of 2020 were ¥2,186,566,003.25, an increase of 0.79% from ¥2,169,508,822.12 at the end of 2019[25]. - The net assets attributable to shareholders decreased by 2.49% to ¥1,708,652,006.75 at the end of 2020 from ¥1,752,293,190.99 at the end of 2019[25]. - The company's fixed assets increased by 28.27% compared to the previous year, amounting to ¥59,169,240.07, primarily due to construction projects and equipment purchases[63]. - Intangible assets grew by 48.92%, totaling ¥31,207,073.52, mainly from the increase in land use rights[63]. - The company has a total of RMB 479,569,950.00 in financial assets, with a fair value change of RMB 2,648,143.84[107]. Corporate Governance and Compliance - The company has not experienced any major litigation or arbitration matters during the reporting period[142]. - There were no significant penalties or rectification measures during the reporting period[143]. - The company has not engaged in any significant related party transactions during the reporting period[145]. - The company has established a dedicated bank account for managing the raised funds, ensuring proper oversight and usage[112]. - The company has committed a total investment of CNY 79,747.59 million, with a cumulative investment of CNY 42,599.49 million, achieving 53.41% of the planned investment[115]. Strategic Focus and Future Plans - The company is committed to becoming China's leading innovative drug enterprise, focusing on patient service and continuous innovation[127]. - The company plans to focus on the development of biopharmaceuticals, small molecule CRO, CDMO, and high-end raw materials in the future[124]. - The company aims to enhance operational efficiency and shareholder value through the acquisition of Hankan Pharmaceutical, which has a strong product line and R&D team[118]. - The company is in the process of issuing stocks to raise funds for the industrialization of its new drug CPT and the first phase of its raw material drug production base[77]. - The company has not proposed any cash dividend distribution plan for the reporting period despite having positive distributable profits[133].

2021-034 武汉海特生物制药股份有限公司 2021 年第一季度报告全文 武汉海特生物制药股份有限公司 2021 年第一季度报告 2021 年 04 月 1 武汉海特生物制药股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈亚、主管会计工作负责人夏汉珍及会计机构负责人(会计主管 人员)羡雯声明：保证季度报告中财务报表的真实、准确、完整。 2 武汉海特生物制药股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 157,828,324.48 | 64,692,430.52 | 143.97% | | 归属于上市公司股东的净利润（元） ...

武汉海特生物制药股份有限公司 2020 年第三季度报告全文 武汉海特生物制药股份有限公司 2020 年第三季度报告 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈亚、主管会计工作负责人夏汉珍及会计机构负责人(会计主管 人员)羡雯声明：保证季度报告中财务报表的真实、准确、完整。 2020-071 2020 年 10 月 1 武汉海特生物制药股份有限公司 2020 年第三季度报告全文 2 武汉海特生物制药股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,128,227,648.15 | 2,169,508,822.12 | | -1.90% | | 归属于上市公司股东的净资 ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥192,340,793.97, a decrease of 39.68% compared to ¥318,890,414.39 in the same period last year[21]. - The net profit attributable to shareholders was a loss of ¥3,779,622.28, representing a decline of 106.77% from a profit of ¥55,806,029.49 in the previous year[21]. - The net cash flow from operating activities was negative at ¥8,486,565.63, a significant drop of 198.31% compared to ¥8,632,837.83 in the same period last year[21]. - The basic earnings per share were -¥0.04, down 107.41% from ¥0.54 in the previous year[21]. - The company's revenue for the reporting period was ¥192,340,793.97, a decrease of 39.68% compared to ¥318,890,414.39 in the same period last year, primarily due to the impact of the pandemic and policy changes in the pharmaceutical industry[72]. - Operating costs increased by 89.40% to ¥74,073,597.75 from ¥39,109,087.21, mainly due to changes in the scope of consolidated financial statements[72]. - Research and development expenses rose by 29.36% to ¥34,819,321.54 from ¥26,916,753.77, reflecting the company's commitment to innovation[73]. - The company reported a total of CNY 67,606,730.40 in inventory as of June 30, 2020, up from CNY 56,582,644.27 at the end of 2019, indicating an increase of about 19.9%[162]. - The company reported a total of CNY 1,008,000 in profit distribution to shareholders[189]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,165,709,092.70, a slight decrease of 0.18% from ¥2,169,508,822.12 at the end of the previous year[21]. - The company's total assets amounted to CNY 2,165,709,092.70, a slight decrease from CNY 2,169,508,822.12 at the end of 2019[162]. - Total liabilities increased to CNY 426,116,592.98 from CNY 409,026,726.23, marking an increase of about 4.2%[164]. - The company's equity attributable to shareholders decreased to CNY 1,731,896,614.88 from CNY 1,752,293,190.99, a decrease of approximately 1.2%[165]. - The total liabilities at the end of the current period were 7,695 million yuan[186]. - The total owner's equity at the end of the current period was 1,725,411,200 CNY, a decrease of 31,303,440 CNY compared to the previous period[192]. Research and Development - The company is focused on the research, production, and sales of innovative biopharmaceuticals, including the injection of mouse nerve growth factor and anti-hepatitis transfer factor[28]. - The company has established a protein structure simulation platform to enhance the success rate of recombinant protein construction[29]. - The company is developing several small molecule generic drugs, including injection of Paracetamol sodium and injection of Esomeprazole sodium, with progress reported as smooth[29]. - The CPT project, a targeted gene-engineered anti-tumor new drug, has received multiple national project grants and is in advanced clinical trial stages[31]. - The company has a strong patent portfolio for CPT, with core patents authorized in 17 countries and regions[31]. - The company has established four major research platforms for drug formulation, including oral immediate release, oral controlled release, injection, and other related formulations[36]. - The company has a dedicated technical center that collaborates with institutions like Huazhong University of Science and Technology and Wuhan University to enhance new drug innovation projects[38]. - The company is actively expanding its product range and has initiated the development of new drugs while enhancing its research capabilities[29]. Market and Sales Strategy - The company primarily adopts a distribution model for sales, participating in centralized procurement tenders across provinces and selling products through licensed pharmaceutical distribution companies[45]. - The company has established a comprehensive market sales service system, enhancing its market planning and cultivation capabilities[60]. - The company established an online and offline marketing network, focusing on key disciplines such as neurosurgery and pediatrics, to adapt to market changes[70]. - The company has a strong market presence in neurology and oncology, with a nationwide sales service network and loyal customer base[61]. Corporate Governance and Compliance - The company will not distribute cash dividends or issue bonus shares for the reporting period[8]. - The company reported no significant litigation or arbitration matters during the reporting period[111]. - There were no penalties or rectification measures taken against the company during the reporting period[112]. - The company did not engage in any major related party transactions during the reporting period[114]. - The company has not undergone any changes in its board of directors, supervisors, or senior management during the reporting period[155]. Investment and Funding - The total amount of raised funds was RMB 797,475,854.40, after deducting fees[86]. - During the reporting period, RMB 499.74 million of the raised funds were invested[84]. - The project for upgrading the biological engineering drug comprehensive preparation base has an investment commitment of RMB 22,000 million, with 95.32% progress[88]. - The company has engaged in entrusted financial management with a total amount of 66,070 million CNY, with no overdue amounts reported[95]. - The company has provided entrusted loans totaling 10,350 million CNY to Beijing Shadong Biotechnology Co., Ltd., with interest rates ranging from 3.85% to 4.75%[97]. Social Responsibility - The company established a poverty alleviation subsidiary in Ying Shan County, investing CNY 22.25 million in agricultural poverty alleviation projects[130]. - The company plans to continue enhancing its poverty alleviation efforts by providing training for local farmers on the cultivation of Dendrobium[132].

证券代码：300683 证券简称：海特生物 公告编号：2020-061 武汉海特生物制药股份有限公司 关于参加湖北辖区上市公司2020年度投资者网上集体接待日 活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 召开时间：2020年8月26日（星期三）14:57-16:27。 召开方式：网络在线交流方式。 一、说明会情况 为便于广大投资者更深入全面地了解公司情况，公司决定以网络在线交流方 式参加湖北证监局、湖北省上市公司协会、深圳市全景网络有限公司联合举办的 "湖北辖区上市公司2020年度投资者网上集体接待日活动"。公司将积极参与活 动并围绕2019年度业绩、公司治理、经营状况、可持续发展等投资者所关心的问 题，通过互动平台与投资者进行沟通交流。 二、说明会召开时间 本次说明会召开时间为 2020 年 8 月 26 日（星期三）14:57-16:27。 三、参加人员 公司出席本次年度网上说明会的人员有公司副总经理、董事会秘书陈煌先 生，财务总监夏汉珍女士。 四、投资者参加方式 本次说明会将通过网上平台采取网络远程的方式举行，投资者可通过 ...